Potential efficacy of some african plants in benign prostatic hyperplasia and prostate cancer

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 11, 2013, Pages 1564-1571

  Russo, Giorgio I ^a   Cimino, Sebastiano ^a   Salamone, Costanza ^a   Madonia, Massimo ^a   Favilla, Vincenzo ^a   Castelli, Tommaso ^a   Morgia, Giuseppe ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

African plants; Benign prostatic hyperplasia; Hypericum perforatum; Hypoxis hemerocallidea; Nerium oleander; Prostate cancer; Pygeum africanum

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANVIRZEL; BICALUTAMIDE; CARDIAC GLYCOSIDE; CASPASE 3; FERULIC ACID; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLAVONOID; FLUTAMIDE; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; HYPOXIS HEMEROCALLIDEA EXTRACT; NERIUM OLEANDER EXTRACT; PENTACYCLIC TRITERPENE; PHYTOSTEROL; PLACEBO; PLANT EXTRACT; PYGEUM AFRICANUM EXTRACT; SITOSTEROL; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AFRICA; APOPTOSIS; ATRIOVENTRICULAR BLOCK; CANCER GROWTH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DEPRESSION; DIARRHEA; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERKALEMIA; HYPERSALIVATION; IC 50; MICTURITION; MYOFIBROBLAST; NAUSEA; NOCTURIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; REVIEW; SINUS BRADYCARDIA; SKIN DISEASE; SLEEP DISORDER; SYSTEMATIC REVIEW; TUMOR GROWTH; URINARY TRACT INFECTION; VOMITING;

HUMANS; HYPERICUM; HYPOXIS; MALE; MEDICINE, TRADITIONAL; NERIUM; PLANT EXTRACTS; PLANTS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PYGEUM;

EID: 84888029706     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575113139990008     Document Type: Review

References (48)

1. Ahmed, A. S.; McGaw, L. J.; Eloff, J. N., Evaluation of pharmacological activities, cytotoxicity and phenolic composition of four Maytenus species used in southern African traditional medicine to treat intestinal infections and diarrhoeal diseases. BMC complementary and alternative medicine 2013, 13 (1), 100.
2. Aruoma, O. I.; Sun, B.; Fujii, H.; Neergheen, V. S.; Bahorun, T.; Kang, K. S.; Sung, M. K., Low molecular proanthocyanidin dietary biofactor Oligonol: Its modulation of oxidative stress, bioefficacy, neuroprotection, food application and chemoprevention potentials. Biofactors 2006, 27 (1-4), 245-65.
3. Sebastiano, C.; Vincenzo, F.; Tommaso, C.; Giuseppe, S.; Marco, R.; Ivana, C.; Giorgio, R.; Massimo, M.; Giuseppe, M., Dietary patterns and prostatic diseases. Front Biosci (Elite Ed) 2012, 4, 195-204.
4. Sanmartin, C.; Plano, D.; Palop, J. A., Selenium compounds and apoptotic modulation: a new perspective in cancer therapy. Mini reviews in medicinal chemistry 2008, 8 (10), 1020-31.
5. Boyle, P.; Ferlay, J., Cancer incidence and mortality in Europe, 2004. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2005, 16 (3), 481-8.
6. Sarkar, F. H.; Adsule, S.; Padhye, S.; Kulkarni, S.; Li, Y., The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini reviews in medicinal chemistry 2006, 6 (4), 401-7.
7. Kumar, A. P.; Graham, H.; Robson, C.; Thompson, I. M.; Ghosh, R., Natural products: potential for developing Phellodendron amurense bark extract for prostate cancer management. Mini reviews in medicinal chemistry 2010, 10 (5), 388-97.
8. Parkin, D. M.; Bray, F. I.; Devesa, S. S., Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37 Suppl 8, S4-66.
9. Yoshimura, Y.; Yamaguchi, O.; Bellamy, F.; Constantinou, C. E., Effect of Pygeum africanum tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and posttreatment with dihydrotestosterone. Urology 2003, 61 (2), 474-8.
10. Geller, J., Pathogenesis and medical treatment of benign prostatic hyperplasia. The Prostate. Supplement 1989, 2, 95-104.
11. Morgia, G.; Mucciardi, G.; Gali, A.; Madonia, M.; Marchese, F.; Di Benedetto, A.; Romano, G.; Bonvissuto, G.; Castelli, T.; Macchione, L.; Magno, C., Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urologia internationalis 2010, 84 (4), 400-6.
12. Morgia, G.; Cimino, S.; Favilla, V.; Russo, G. I.; Squadrito, F.; Mucciardi, G.; Masieri, L.; Minutoli, L.; Grosso, G.; Castelli, T., Effects of Serenoa Repens, Selenium and Lycopene (Profluss(R) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study. International braz j urol: official journal of the Brazilian Society of Urology 2013, 39 (2), 214-221.
13. He, M.; Young, C. Y., New approaches to target the androgen receptor and STAT3 for prostate cancer treatments. Mini reviews in medicinal chemistry 2009, 9 (3), 395-400.
14. Cristoni, A.; Di Pierro, F.; Bombardelli, E., Botanical derivatives for the prostate. Fitoterapia 2000, 71 Suppl 1, S21-8.
15. Yablonsky, F.; Nicolas, V.; Riffaud, J. P.; Bellamy, F., Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. The Journal of urology 1997, 157 (6), 2381-7.
16. Boulbes, D.; Soustelle, L.; Costa, P.; Haddoum, M.; Bali, J. P.; Hollande, F.; Magous, R., Pygeum africanum extract inhibits proliferation of human cultured prostatic fibroblasts and myofibroblasts. BJU international 2006, 98 (5), 1106-13.
17. Cimino, S.; Sortino, G.; Favilla, V.; Castelli, T.; Madonia, M.; Sansalone, S.; Russo, G. I.; Morgia, G., Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxidative medicine and cellular longevity 2012, 2012, 632959.
18. Quiles, M. T.; Arbos, M. A.; Fraga, A.; de Torres, I. M.; Reventos, J.; Morote, J., Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). The Prostate 2010, 70 (10), 1044-53.
19. Wilt, T.; Ishani, A.; Mac Donald, R.; Rutks, I.; Stark, G., Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002, (1), CD001044.
20. Larre, S.; Camparo, P.; Comperat, E.; Boulbes, D.; Haddoum, M.; Baulande, S.; Soularue, P.; Costa, P.; Cussenot, O., Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian journal of andrology 2012, 14 (3), 499-504.
21. Loreto, C.; Barbagli, G.; Djinovic, R.; Vespasiani, G.; Carnazza, M. L.; Miano, R.; Musumeci, G.; Sansalone, S., Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptor (DR5) in Peyronie's disease. A biomolecular study of apoptosis activation. The journal of sexual medicine 2011, 8 (1), 109-15.
22. Shenouda, N. S.; Sakla, M. S.; Newton, L. G.; Besch-Williford, C.; Greenberg, N. M.; MacDonald, R. S.; Lubahn, D. B., Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine 2007, 31 (1), 72-81.
23. Schleich, S.; Papaioannou, M.; Baniahmad, A.; Matusch, R., Activity-guided isolation of an antiandrogenic compound of Pygeum africanum. Planta medica 2006, 72 (6), 547-51.
24. Schleich, S.; Papaioannou, M.; Baniahmad, A.; Matusch, R., Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity. Planta medica 2006, 72 (9), 807-13.
25. Roell, D.; Baniahmad, A., The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Molecular and cellular endocrinology 2011, 332 (1-2), 1-8.
26. Handratta, V. D.; Vasaitis, T. S.; Njar, V. C.; Gediya, L. K.; Kataria, R.; Chopra, P.; Newman, D., Jr.; Farquhar, R.; Guo, Z.; Qiu, Y.; Brodie, A. M., Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of medicinal chemistry 2005, 48 (8), 2972-84.
27. Harrer, G.; Schulz, V., Clinical investigation of the antidepressant effectiveness of hypericum. Journal of geriatric psychiatry and neurology 1994, 7 Suppl 1, S6-8.
28. Hostanska, K.; Reichling, J.; Bommer, S.; Weber, M.; Saller, R., Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e. V 2003, 56 (1), 121-32.
29. Neary, J. T.; Bu, Y., Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain research 1999, 816 (2), 358-63.
30. Theodossiou, T. A.; Noronha-Dutra, A.; Hothersall, J. S., Mitochondria are a primary target of hypericin phototoxicity: synergy of intracellular calcium mobilisation in cell killing. The international journal of biochemistry & cell biology 2006, 38 (11), 1946-56.
31. Cindolo, L.; Cantile, M.; Vacherot, F.; Terry, S.; de la Taille, A., Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urologia internationalis 2007, 79 (4), 287-96.
32. Sella, A.; Konichezky, M.; Flex, D.; Sulkes, A.; Baniel, J., Low PSA metastatic androgen-independent prostate cancer. European urology 2000, 38 (3), 250-4.
33. Bonkhoff, H.; Stein, U.; Remberger, K., Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Human pathology 1995, 26 (2), 167-70.
34. Xie, X.; Hudson, J. B.; Guns, E. S., Tumor-specific and photodependent cytotoxicity of hypericin in the human LNCaP prostate tumor model. Photochemistry and photobiology 2001, 74 (2), 221-5.
35. Martarelli, D.; Martarelli, B.; Pediconi, D.; Nabissi, M. I.; Perfumi, M.; Pompei, P., Hypericum perforatum methanolic extract inhibits growth of human prostatic carcinoma cell line orthotopically implanted in nude mice. Cancer letters 2004, 210 (1), 27-33.
36. Drewes, S. E.; Elliot, E.; Khan, F.; Dhlamini, J. T.; Gcumisa, M. S., Hypoxis hemerocallidea--not merely a cure for benign prostate hyperplasia. Journal of ethnopharmacology 2008, 119 (3), 593-8.
37. Nicoletti, M.; Galeffi, C.; Messana, I.; Marini-Bettolo, G. B., Hypoxidaceae. Medicinal uses and the norlignan constituents. Journal of ethnopharmacology 1992, 36 (2), 95-101.
38. Dedhia, R. C.; McVary, K. T., Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of urology 2008, 179 (6), 2119-25.
39. Berges, R. R.; Windeler, J.; Trampisch, H. J.; Senge, T., Randomised, placebo-controlled, double-blind clinical trial of betasitosterol in patients with benign prostatic hyperplasia. Betasitosterol Study Group. Lancet 1995, 345 (8964), 1529-32.
40. Berges, R. R.; Kassen, A.; Senge, T., Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU international 2000, 85 (7), 842-6.
41. Laporta, O.; Funes, L.; Garzon, M. T.; Villalain, J.; Micol, V., Role of membranes on the antibacterial and anti-inflammatory activities of the bioactive compounds from Hypoxis rooperi corm extract. Archives of biochemistry and biophysics 2007, 467 (1), 119-31.
42. Altavilla, D.; Bitto, A.; Polito, F.; Irrera, N.; Marini, H.; Arena, S.; Favilla, V.; Squadrito, F.; Morgia, G.; Minutoli, L., The combination of Serenoa repens, selenium and lycopene is more effective than serenoa repens alone to prevent hormone dependent prostatic growth. The Journal of urology 2011, 186 (4), 1524-9.
43. Rashan, L. J.; Franke, K.; Khine, M. M.; Kelter, G.; Fiebig, H. H.; Neumann, J.; Wessjohann, L. A., Characterization of the anticancer properties of monoglycosidic cardenolides isolated from Nerium oleander and Streptocaulon tomentosum. Journal of ethnopharmacology 2011, 134 (3), 781-8.
44. Bandara, V.; Weinstein, S. A.; White, J.; Eddleston, M., A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning. Toxicon: official journal of the International Society on Toxinology 2010, 56 (3), 273-81.
45. McConkey, D. J.; Lin, Y.; Nutt, L. K.; Ozel, H. Z.; Newman, R. A., Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer research 2000, 60 (14), 3807-12.
46. Cronauer, M. V.; Hittmair, A.; Eder, I. E.; Hobisch, A.; Culig, Z.; Ramoner, R.; Zhang, J.; Bartsch, G.; Reissigl, A.; Radmayr, C.; Thurnher, M.; Klocker, H., Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. The Prostate 1997, 31 (4), 223-33.
47. Smith, J. A.; Madden, T.; Vijjeswarapu, M.; Newman, R. A., Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochemical pharmacology 2001, 62 (4), 469-72.
48. McVary, K. T.; Roehrborn, C. G.; Avins, A. L.; Barry, M. J.; Bruskewitz, R. C.; Donnell, R. F.; Foster, H. E., Jr.; Gonzalez, C. M.; Kaplan, S. A.; Penson, D. F.; Ulchaker, J. C.; Wei, J. T., Update on AUA guideline on the management of benign prostatic hyperplasia. The Journal of urology 2011, 185 (5), 1793-803.